{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:41:41Z","timestamp":1790379701872,"version":"4.1.0"},"reference-count":58,"publisher":"Baishideng Publishing Group Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2016]]},"DOI":"10.3748\/wjg.v22.i4.1421","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T03:31:43Z","timestamp":1453692703000},"page":"1421","source":"Crossref","is-referenced-by-count":124,"title":["New approaches in the treatment of hepatitis C"],"prefix":"10.3748","volume":"22","author":[{"given":"Roc\u00edo","family":"Gonz\u00e1lez-Grande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.051"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1213651"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Belperio PS, Backus LI, Ross D, Neuhauser MM, Mole LA. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. J Manag Care Spec Pharm 2014;20:533-540.","DOI":"10.18553\/jmcp.2014.20.6.533"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60538-9"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.145.152"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0381-2"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro2014.04.045"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0785"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.116\/j.jhep2014.12.025"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"ref15","unstructured":"AASLD and Infectious Diseases society of América (IDSA). Uptodate to recommendations for testing, managing and treating hepatitis C: management of acute HCV infection Avaiable from: URL: http\/\/www.hcvguidelines.org on 02\/12\/; 2014;."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305771"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60494-3"},{"key":"ref20","unstructured":"Jensen DM, Oleary J, Pcokros P, Sherman K, Kwo P, Mailliard M, Kowdley K, Muir A, Dickson R, Ramani A, Manns M, Lok A, Akushevich L, Nelson D, Fried M. Safety and efficacy of Sofosbuvir-containing regimens for hepatitis C: Real-world experience in a diverse, longitudinal observational cohort. [Abstract 45] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2014;."},{"key":"ref21","unstructured":"Dieterich D, Bacon B, Flamm S, Kowdley K, Milligan S, Tsai N, Younossi Z, Lawitz E. Evaluation of sofosbuvir and simprevir based regimens in the TRIO network-Academic and community treatment of a real-world, heterogeneous population. [Abstract 46] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2014;."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306227"},{"key":"ref26","unstructured":"Flamm SL, Everson GT, Charlton . Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with descomensated cirrosis: preliminary results of a prospective, multicenter study. [Abstract L5] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2014;."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61793-1"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"ref32","unstructured":"Lawitz E, Poordad F, Gutierrez JA, Evans B, Hwang P, Howe A, Feng HP, Robertson M, Wahl J, Barr E, Hber B. C-SWITZ: Grazoprevir (MK-5172) Elbasvir (MK-8742) Sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with or without cirrhosis, for duration 4, 6, or 8 weeks (interim results). [Abstract LB-33] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2014;."},{"key":"ref33","unstructured":"Poordad F, Sievert W, Mollison L, Brau N, Levin J, Sepe T, Lee S, Boyer N, Bronowicki JP, Jacobson IM. Alloral, fixed-dosed combination therapy with daclatasvir\/asunaprevir\/beclabuvie for non-cirrhotic patients with chronic HCV genotype 1 infection: UNITY-1 phase 3 SVR 12 results. [Abstract LB-7] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2014;."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3868"},{"key":"ref35","unstructured":"Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir in combination with PegIFN and ribavirin dor 12 weeks provides high SVR rates in HCV-Infected getype 2 or 3 treatment-experienced patients with or without compensated cirrhosis: results from the LONESTAR-2 study. [Abstract 48] Asian Pacific Association for the Study of the Liver (APASL) 2014;."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12711"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Gane E, Hyland RH, An Di, Pang PS, Symonds WT, McHutchinson , Stedman CA. Ledipasvis\/sofosbuvir fixed-dose combination is safe and effective in difficult-to-treat populations including GT 3 patients, descompesated GT1 patients, and GT 1 patients with prior sofosbuvir experience. [Abstract 0-6] 49th European Association for the Study of the Liver International Liver Congress (EASL) 2014;.","DOI":"10.1016\/S0168-8278(14)60008-8"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2013.06.014"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60247-0"},{"key":"ref44","unstructured":"Kapoor R, Kohli A, Sidhartahan S, Sims Z, Pertersen T, Osinusi A, Nelson A, Silk R, Kotb C, Sugarman K, Lam BP, Pang PS, Subramanian M, McHutchison JG, Masur H, Kottilil S, Rustgi VK. Treatment of hepatitis C genotype 4 with ledipasvir and sofosbuvir for 12 weeks: results of the SYNERGY trial. [Abstract 240] 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2014;."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.044"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00310-6"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.023"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i44.16409"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients. Ann Pharmacother 2015;49:674-687.","DOI":"10.1177\/1060028015576180"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.001"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27770"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408921"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i2.213"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007;14:697-703.","DOI":"10.1111\/j.1365-2893.2007.00868.x"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202770"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Johnson RJ, Gretch DR, Couser WG, Alpers CE, Wilson J, Chung M, Hart J, Willson R. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994;46:1700-1704.","DOI":"10.1038\/ki.1994.471"},{"key":"ref57","unstructured":"González-Grande R, Jiménez-Pérez M, Sáez-Gómez AB, Rodrigo-López JM. Metabolic syndrome after liver transplantation. Liver transplantation Technical issuesand complications Croatia: ed InTech; 2012;349-360."},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26892"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v22\/i4\/1421.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T23:53:41Z","timestamp":1567554821000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v22\/i4\/1421.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v22.i4.1421","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}